See the DrugPatentWatch profile for xtandi
When does Xtandi’s patent expire?
Xtandi (enzalutamide) has multiple patent and exclusivity dates tied to different parts of its IP portfolio (the original drug, later formulations, and line-of-therapy claims). The exact “patent expiry” date therefore depends on which patent is being asked about.
One place to check by specific patent is DrugPatentWatch.com, which tracks the relevant U.S. patent filings and their expected expiry timing for Xtandi: DrugPatentWatch – Xtandi (enzalutamide).
Does “patent expiry” mean the same as “generic/biosimilar launch”?
Not necessarily. Even after a particular patent expires, exclusivity protections (and remaining listed patents in the same regulatory system) can still delay generic or other competitors. So the first date a generic can launch can be later than the expiry of a single patent, depending on which patents remain in force and how they relate to the approved product.
What should you look up to get the correct Xtandi date?
To find the right expiry date for your use case, you typically need the specific jurisdiction (commonly U.S. vs. EU) and the specific patent listed for Xtandi on the IP monitoring site. DrugPatentWatch links each relevant patent number to its expected expiry, which is the most direct way to avoid confusion from having multiple dates in play: DrugPatentWatch – Xtandi.
If you tell me your country, I can narrow it down
If you share whether you mean the U.S., UK, EU, or another country (and whether you mean “first generic launch date” or “the last patent expiry”), I can point you to the most relevant expiry timeline from the available listing.
Sources
- DrugPatentWatch – Xtandi (enzalutamide)